Stocks
BioMarin Pharmaceutical Financial Statements (BMRN) |
||||||||||
| BioMarin Pharmaceuticalsmart-lab.ru | % | 2021 | 2022 | 2022 | 2023 | LTM ? | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| Report date | 25.02.2022 | 31.03.2022 | 31.12.2022 | 27.02.2023 | 26.02.2024 | 26.04.2024 | ||||
| Currency | USD | USD | USD | USD | USD | USD | ||||
| Financial report URL | ||||||||||
| Revenue, bln rub | ? | 1 846 | 2 096 | 2 096 | 2 419 | 2 530 | ||||
| Operating Income, bln rub | -60.0 | 149.6 | 57.5 | 157.6 | 200.8 | |||||
| EBITDA, bln rub | ? | 48.0 | 165.7 | 159.5 | 262.0 | 308.0 | ||||
| Net profit, bln rub | ? | -64.1 | 141.6 | 141.6 | 167.6 | 238.1 | ||||
| OCF, bln rub | ? | 304.5 | 175.9 | 175.9 | 159.3 | 210.1 | ||||
| CAPEX, bln rub | ? | 119.2 | 121.0 | 131.5 | 107.6 | 94.2 | ||||
| FCF, bln rub | ? | 185.3 | 54.9 | 44.4 | 51.6 | 115.9 | ||||
| Dividend payout, bln rub | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |||||
| Ordinary share dividend yield, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | ||||
| Dividend payout ratio, % | 0.00% | 0.00% | 0.00% | 0.00% | 0 | |||||
| OPEX, bln rub | 1 458 | 1 946 | 1 571 | 1 685 | 1 774 | |||||
| Cost of production, bln rub | 470.5 | 483.7 | 483.7 | 577.1 | 554.9 | |||||
| R&D, bln rub | 628.8 | 649.6 | 649.6 | 746.8 | 807.5 | |||||
| Interest expenses, bln rub | 15.3 | 16.0 | 16.0 | 17.3 | 17.0 | |||||
| Assets, bln rub | 6 003 | 6 063 | 6 375 | 6 375 | 6 842 | 6 873 | ||||
| Net Assets, bln rub | ? | 4 271 | 4 391 | 4 603 | 4 603 | 4 952 | 5 074 | |||
| Debt, bln rub | 1 079 | 1 080 | 1 083 | 1 083 | 1 134 | 1 088 | ||||
| Cash, bln rub | 1 014 | 1 056 | 1 292 | 1 292 | 1 074 | 1 047 | ||||
| Net debt, bln rub | 65.2 | 23.8 | -208.5 | -208.5 | 60.1 | 41.4 | ||||
| Ordinary share price, rub | 88.4 | 77.1 | 103.5 | 103.5 | 96.4 | 79.7 | ||||
| Number of ordinary shares, mln | 182.9 | 185.3 | 185.3 | 187.8 | 188.9 | |||||
| Market cap, bln rub | 16 155 | 0 | 19 173 | 19 173 | 18 111 | 15 058 | ||||
| EV, bln rub | ? | 16 220 | 24 | 18 965 | 18 965 | 18 171 | 15 100 | |||
| Book value, bln rub | 3 686 | 3 821 | 4 068 | 4 068 | 4 461 | 4 598 | ||||
| EPS, rub | ? | -0.35 | 0.76 | 0.76 | 0.89 | 1.26 | ||||
| FCF/share, rub | 1.01 | 0.30 | 0.24 | 0.27 | 0.61 | |||||
| BV/share, rub | 20.2 | 22.0 | 22.0 | 23.7 | 24.3 | |||||
| EBITDA margin, % | ? | 2.60% | 7.90% | 7.61% | 10.8% | 12.2% | ||||
| Net margin, % | ? | -3.47% | 6.75% | 6.75% | 6.93% | 9.41% | ||||
| FCF yield, % | ? | 1.15% | 0.00% | 0.29% | 0.23% | 0.29% | 0.77% | |||
| ROE, % | ? | -1.50% | 0.00% | 3.08% | 3.08% | 3.39% | 4.69% | |||
| ROA, % | ? | -1.07% | 0.00% | 2.22% | 2.22% | 2.45% | 3.46% | |||
| P/E | ? | -252.1 | 135.4 | 135.4 | 108.0 | 63.2 | ||||
| P/FCF | 87.2 | 349.0 | 432.2 | 350.7 | 129.9 | |||||
| P/S | ? | 8.75 | 9.15 | 9.15 | 7.49 | 5.95 | ||||
| P/BV | ? | 4.38 | 0.00 | 4.71 | 4.71 | 4.06 | 3.27 | |||
| EV/EBITDA | ? | 337.7 | 114.5 | 118.9 | 69.4 | 49.0 | ||||
| Debt/EBITDA | 1.36 | -1.26 | -1.31 | 0.23 | 0.13 | |||||
| R&D/CAPEX, % | 527.4% | 537.0% | 493.8% | 694.0% | 857.1% | |||||
| CAPEX/Revenue, % | 6.46% | 5.77% | 6.28% | 4.45% | 3.72% | |||||
| BioMarin Pharmaceutical shareholders | ||||||||||
